Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
70
TAK Quote, Financials, Valuation and Earnings
Last price:
$15.58
Seasonality move
:
4.51%
Day range:
$15.52 - $15.62
52-week range:
$12.80 - $15.69
Dividend yield:
4.24%
P/E ratio:
197.72x
P/S ratio:
1.68x
P/B ratio:
1.02x
Volume:
1.3M
Avg. volume:
2.9M
1-year change:
18.3%
Market cap:
$49.2B
Revenue:
$30.1B
EPS (TTM):
$0.08
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$7.8B | -- | 3.82% | -- | $17.93 |
|
AMGN
Amgen, Inc.
|
$9B | $5.01 | 4.54% | 310.03% | $325.88 |
|
BMY
Bristol Myers Squibb Co.
|
$11.8B | $1.52 | -0.85% | 4631.67% | $55.09 |
|
NVS
Novartis AG
|
$13.9B | $2.31 | 5.75% | 37.94% | $134.88 |
|
PFE
Pfizer Inc.
|
$16.5B | $0.63 | -4.58% | 694.41% | $28.62 |
|
SNY
Sanofi
|
$14.2B | $1.57 | -6.06% | 28.6% | $59.35 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$15.58 | $17.93 | $49.2B | 197.72x | $0.32 | 4.24% | 1.68x |
|
AMGN
Amgen, Inc.
|
$333.89 | $325.88 | $179.8B | 25.81x | $2.38 | 2.85% | 5.04x |
|
BMY
Bristol Myers Squibb Co.
|
$54.69 | $55.09 | $111.3B | 18.47x | $0.62 | 4.54% | 2.32x |
|
NVS
Novartis AG
|
$138.88 | $134.88 | $266.5B | 18.94x | $3.99 | 2.88% | 5.03x |
|
PFE
Pfizer Inc.
|
$25.03 | $28.62 | $142.3B | 14.59x | $0.43 | 6.87% | 2.28x |
|
SNY
Sanofi
|
$48.36 | $59.35 | $117.9B | 12.07x | $2.20 | 4.54% | 2.78x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
39.45% | -0.563 | 68.02% | 0.64x |
|
AMGN
Amgen, Inc.
|
85.02% | 0.027 | 35.92% | 0.82x |
|
BMY
Bristol Myers Squibb Co.
|
73.34% | -0.073 | 56.92% | 0.94x |
|
NVS
Novartis AG
|
41.94% | 0.086 | 12.99% | 0.58x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
|
SNY
Sanofi
|
22.66% | -0.244 | -- | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$3.6B | $763.2M | 0.33% | 0.55% | 10.11% | $2B |
|
AMGN
Amgen, Inc.
|
$6.5B | $2.6B | 10.74% | 95.55% | 26.65% | $4.2B |
|
BMY
Bristol Myers Squibb Co.
|
$8.1B | $3.8B | 8.82% | 34.7% | 31.46% | $6B |
|
NVS
Novartis AG
|
$10.3B | $4.2B | 19.37% | 33.87% | 30.24% | $5.7B |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
|
SNY
Sanofi
|
$8.8B | $1.9B | 9.89% | 12.45% | 14.08% | $218.7M |
Takeda Pharmaceutical Co., Ltd. vs. Competitors
-
Which has Higher Returns TAK or AMGN?
Amgen, Inc. has a net margin of -1.05% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of 33.55%. Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55% beat Amgen, Inc.'s return on equity of 95.55%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B AMGNAmgen, Inc.67.85% $5.93 $64.2B -
What do Analysts Say About TAK or AMGN?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of $17.93, signalling upside risk potential of 14.94%. On the other hand Amgen, Inc. has an analysts' consensus of $325.88 which suggests that it could fall by -1.69%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Amgen, Inc., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Amgen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical Co., Ltd.3 0 0 AMGNAmgen, Inc.10 15 2 -
Is TAK or AMGN More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of 0.032, which suggesting that the stock is 96.811% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.
-
Which is a Better Dividend Stock TAK or AMGN?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.32 per share corresponding to a yield of 4.24%. Amgen, Inc. offers a yield of 2.85% to investors and pays a quarterly dividend of $2.38 per share. Takeda Pharmaceutical Co., Ltd. pays 242.25% of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TAK or AMGN?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.5B, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M is lower than Amgen, Inc.'s net income of $3.2B. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 197.72x while Amgen, Inc.'s PE ratio is 25.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.68x versus 5.04x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical Co., Ltd.1.68x 197.72x $7.5B -$79.5M AMGNAmgen, Inc.5.04x 25.81x $9.6B $3.2B
-
Which has Higher Returns TAK or BMY?
Bristol Myers Squibb Co. has a net margin of -1.05% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of 17.96%. Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55% beat Bristol Myers Squibb Co.'s return on equity of 34.7%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B BMYBristol Myers Squibb Co.66% $1.08 $69.6B -
What do Analysts Say About TAK or BMY?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of $17.93, signalling upside risk potential of 14.94%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $55.09 which suggests that it could grow by 0.41%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Bristol Myers Squibb Co., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Bristol Myers Squibb Co..
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical Co., Ltd.3 0 0 BMYBristol Myers Squibb Co.4 18 1 -
Is TAK or BMY More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of 0.032, which suggesting that the stock is 96.811% less volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.363%.
-
Which is a Better Dividend Stock TAK or BMY?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.32 per share corresponding to a yield of 4.24%. Bristol Myers Squibb Co. offers a yield of 4.54% to investors and pays a quarterly dividend of $0.62 per share. Takeda Pharmaceutical Co., Ltd. pays 242.25% of its earnings as a dividend. Bristol Myers Squibb Co. pays out 54.44% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical Co., Ltd.'s is not.
-
Which has Better Financial Ratios TAK or BMY?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.5B, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.2B. Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M is lower than Bristol Myers Squibb Co.'s net income of $2.2B. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 197.72x while Bristol Myers Squibb Co.'s PE ratio is 18.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.68x versus 2.32x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical Co., Ltd.1.68x 197.72x $7.5B -$79.5M BMYBristol Myers Squibb Co.2.32x 18.47x $12.2B $2.2B
-
Which has Higher Returns TAK or NVS?
Novartis AG has a net margin of -1.05% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of 28.26%. Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55% beat Novartis AG's return on equity of 33.87%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B NVSNovartis AG74.59% $2.02 $76.8B -
What do Analysts Say About TAK or NVS?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of $17.93, signalling upside risk potential of 14.94%. On the other hand Novartis AG has an analysts' consensus of $134.88 which suggests that it could fall by -2.88%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Novartis AG, analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Novartis AG.
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical Co., Ltd.3 0 0 NVSNovartis AG1 6 2 -
Is TAK or NVS More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of 0.032, which suggesting that the stock is 96.811% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.525, suggesting its less volatile than the S&P 500 by 47.542%.
-
Which is a Better Dividend Stock TAK or NVS?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.32 per share corresponding to a yield of 4.24%. Novartis AG offers a yield of 2.88% to investors and pays a quarterly dividend of $3.99 per share. Takeda Pharmaceutical Co., Ltd. pays 242.25% of its earnings as a dividend. Novartis AG pays out 55.39% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical Co., Ltd.'s is not.
-
Which has Better Financial Ratios TAK or NVS?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.5B, which are smaller than Novartis AG quarterly revenues of $13.9B. Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M is lower than Novartis AG's net income of $3.9B. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 197.72x while Novartis AG's PE ratio is 18.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.68x versus 5.03x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical Co., Ltd.1.68x 197.72x $7.5B -$79.5M NVSNovartis AG5.03x 18.94x $13.9B $3.9B
-
Which has Higher Returns TAK or PFE?
Pfizer Inc. has a net margin of -1.05% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of 21.32%. Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About TAK or PFE?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of $17.93, signalling upside risk potential of 14.94%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.36%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Pfizer Inc., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical Co., Ltd.3 0 0 PFEPfizer Inc.7 15 1 -
Is TAK or PFE More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of 0.032, which suggesting that the stock is 96.811% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock TAK or PFE?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.32 per share corresponding to a yield of 4.24%. Pfizer Inc. offers a yield of 6.87% to investors and pays a quarterly dividend of $0.43 per share. Takeda Pharmaceutical Co., Ltd. pays 242.25% of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TAK or PFE?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.5B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 197.72x while Pfizer Inc.'s PE ratio is 14.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.68x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical Co., Ltd.1.68x 197.72x $7.5B -$79.5M PFEPfizer Inc.2.28x 14.59x $16.7B $3.6B
-
Which has Higher Returns TAK or SNY?
Sanofi has a net margin of -1.05% compared to Takeda Pharmaceutical Co., Ltd.'s net margin of 36.7%. Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55% beat Sanofi's return on equity of 12.45%.
Company Gross Margin Earnings Per Share Invested Capital TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B SNYSanofi72.13% $1.83 $106.5B -
What do Analysts Say About TAK or SNY?
Takeda Pharmaceutical Co., Ltd. has a consensus price target of $17.93, signalling upside risk potential of 14.94%. On the other hand Sanofi has an analysts' consensus of $59.35 which suggests that it could grow by 22.73%. Given that Sanofi has higher upside potential than Takeda Pharmaceutical Co., Ltd., analysts believe Sanofi is more attractive than Takeda Pharmaceutical Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TAKTakeda Pharmaceutical Co., Ltd.3 0 0 SNYSanofi5 2 0 -
Is TAK or SNY More Risky?
Takeda Pharmaceutical Co., Ltd. has a beta of 0.032, which suggesting that the stock is 96.811% less volatile than S&P 500. In comparison Sanofi has a beta of 0.446, suggesting its less volatile than the S&P 500 by 55.394%.
-
Which is a Better Dividend Stock TAK or SNY?
Takeda Pharmaceutical Co., Ltd. has a quarterly dividend of $0.32 per share corresponding to a yield of 4.24%. Sanofi offers a yield of 4.54% to investors and pays a quarterly dividend of $2.20 per share. Takeda Pharmaceutical Co., Ltd. pays 242.25% of its earnings as a dividend. Sanofi pays out 66.53% of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical Co., Ltd.'s is not.
-
Which has Better Financial Ratios TAK or SNY?
Takeda Pharmaceutical Co., Ltd. quarterly revenues are $7.5B, which are smaller than Sanofi quarterly revenues of $12.2B. Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M is lower than Sanofi's net income of $4.5B. Notably, Takeda Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 197.72x while Sanofi's PE ratio is 12.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical Co., Ltd. is 1.68x versus 2.78x for Sanofi. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TAKTakeda Pharmaceutical Co., Ltd.1.68x 197.72x $7.5B -$79.5M SNYSanofi2.78x 12.07x $12.2B $4.5B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
